A continuum of inherited telomere dysfunction links TERT rare variants to age-related diseases

C Christopher Reilly (6Division of Hematologic Malignancies, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, United States) S Sean Wen A Amelia Grosskopf (1Dana-Farber Cancer Institute, Medical Oncology, Boston, United States) J Jessica Knapp (Department of Environmental and Geosciences, Lund University, Lund, Sweden.) T Thomas McGovern (3Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, United States) S Steven Senese (5Harvard T. H. Chan School of Public Health, Department of Epidemiology, Boston, United States) D Dimitris Gazgalis (4Dana-Farber Cancer Institute, Pediatric Oncology, Boston, United States) P Priyanka Samanta F Frederick Tsai (1Dana-Farber Cancer Institute, Medical Oncology, Boston, United States) A Andrew Gehrke (1Dana-Farber Cancer Institute, Medical Oncology, Boston, United States) J Jeanette Walter (4Dana-Farber Cancer Institute, Pediatric Oncology, Boston, United States) R Rafael Campos (3AstraZeneca, Discovery Sciences Biopharmaceuticals R&D, Cambridge, United Kingdom) M Marcin Karpinski O Oliver Burren (3AstraZeneca, Discovery Sciences Biopharmaceuticals R&D, Cambridge, United Kingdom) F Fengyuan Hu S Slavé Petrovski S Suneet Agarwal B Benjamin Raby (8Brigham and Women's Hospital, Channing Division of Network Medicine, Boston, United States) I Immaculata De Vivo (3Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, United States) J Jianwei Che (Department of Cancer Biology, Dana-Farber Cancer Institute) M Margarete Fabre G George Vassiliou J Jonathan Mitchell R R. Coleman Lindsley (Dana-Farber Cancer Institute, Boston, Massachusetts, United States)

Abstract

Abstract Background Telomere biology disorders (TBDs) are caused by pathogenic variants in telomerase reverse transcriptase (TERT) and other telomere-related genes and are defined by premature telomere shortening and multiorgan manifestations, including bone marrow failure, pulmonary fibrosis, liver disease, osteoporosis, and cancer. Although TBDs are clinically rare, TERT rare missense variants occur in ~1% of the population with 90% classified as variants of uncertain significance. This disparity suggests that classical TBDs represent the extreme end of a broader continuum of telomere dysfunction. To quantify this latent potential, we generated a population-scale functional atlas of TERT missense variants in the UK Biobank and assessed their association with telomere length (TL), clonal hematopoiesis (CH), and clinical phenotypes. Methods We identified TERT rare variants (max population allele frequency <0.001) in 462,666 UK Biobank participants. To define their functional impact, we developed a cell-based assay to quantify telomere extension relative to wild-type (WT) TERT. We performed molecular simulations and free energy (ΔΔG) calculations using the cryo-EM structure of telomerase bound to TPP1. Functional scores were integrated with a common variant-derived TL polygenic risk score (PRS) to define their impact on TL, hematologic traits, CH, and clinical phenotypes. Results To establish functional thresholds, we benchmarked our assay using 9 common variants and 120 TBD-associated variants. Common variants did not impact telomere extension, while all TBD-associated variants were impaired: 62% showed no extension ('severe') and 38% had reduced extension ('intermediate'). Among 601TERT missense variants, 69% were impaired (13% severe, 56% intermediate) in 1297 UK Biobank participants. Severe variants clustered in domains that form the active site (C-terminal extension domain, CTE: 29%; reverse transcriptase domain, RTD: 18%) or bind to TPP1 (telomerase-essential N-terminal domain, TEN: 25%). Variants in the telomerase RNA binding domain (TRBD) had fewer severe (7%) but more intermediate variants, yielding similar impairment rates (69% vs 74%, p=0.28). No severe variants occurred in the linker domain. To investigate mechanisms of impairment, we modeled 14 variants across five multiallelic positions (TEN:G135, TRBD:R358, RTD:R669/R756, CTE:R962) that had variants with divergent functional scores. Functional impairment correlated with increased ΔΔG (>3 kcal/mol, r = -0.75, p=0.007) and reduced side-chain contacts with TPP1, TERC, or the RNA:DNA duplex. Severe variants showed disrupted interactions and intermediate variants showed partial contact loss or altered flexibility, indicating domain-specific mechanisms of dysfunction and a gradient of severity across alleles. To determine whether TERT functional impairment correlated with in vivo telomere shortening, we analyzed leukocyte TL in UK Biobank participants. Severe variants were associated with shorter TL compared to controls (β = -1.55, p<0.0001), similar to protein-truncating variants (β= -1.27). Intermediate variants had a moderate effect (β = -0.55, p<0.0001), while preserved variants had minimal impact (β = -0.09). TL effects were strongest for variants in the TEN, RTD, and CTE domains. The PRS modified TL across functional groups, but its effect was attenuated with increasing TERT variant impairment (standardized interaction coefficients: preserved 1.7, intermediate 0.9, severe 0.3). Among intermediate carriers, TL ranged from preserved-like to severe-like across PRS quartiles. We examined whether TERT functional impairment was associated with clinical phenotypes. Intermediate and severe, but not preserved, variants were associated with bone marrow dysfunction (higher MCV, lower RBC count, lower platelet mass), TBD-related CH with somatic PPM1D or TERT promoter mutations (OR=22 and 118, both p<0.0001), interstitial lung disease (OR=7.9 and 66.1, both p<0.0001). Severe variants were associated with aplastic anemia (OR=10.4, p=0.012) and osteoporosis (OR=29.5, p<0.0001). Conclusion Most germline TERT rare missense variants are functionally impaired (69%) with domain-specific effects linked to shorter TL and manifestations of telomere dysfunction including TBD-related CH and clinical phenotypes. Polygenic background modulates – but does not offset – the effects of impaired TERT variants, revealing a continuum of inherited telomere dysfunction shaped by rare and common variants.

Article Details

Journal Blood
Volume / Issue Vol. 146, Issue Supplement 1
Published November 03, 2025
Pages 749-749
ISSN 0006-4971
Publisher Elsevier BV

Journal Info

Blood

Elsevier BV

ISSN: 0006-4971 Health Sciences

Authors (24)

C

Christopher Reilly

6Division of Hematologic Malignancies, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, United States

S

Sean Wen

A

Amelia Grosskopf

1Dana-Farber Cancer Institute, Medical Oncology, Boston, United States

J

Jessica Knapp

Department of Environmental and Geosciences, Lund University, Lund, Sweden.

T

Thomas McGovern

3Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, United States

S

Steven Senese

5Harvard T. H. Chan School of Public Health, Department of Epidemiology, Boston, United States

D

Dimitris Gazgalis

4Dana-Farber Cancer Institute, Pediatric Oncology, Boston, United States

P

Priyanka Samanta

F

Frederick Tsai

1Dana-Farber Cancer Institute, Medical Oncology, Boston, United States

A

Andrew Gehrke

1Dana-Farber Cancer Institute, Medical Oncology, Boston, United States

J

Jeanette Walter

4Dana-Farber Cancer Institute, Pediatric Oncology, Boston, United States

R

Rafael Campos

3AstraZeneca, Discovery Sciences Biopharmaceuticals R&D, Cambridge, United Kingdom

M

Marcin Karpinski

O

Oliver Burren

3AstraZeneca, Discovery Sciences Biopharmaceuticals R&D, Cambridge, United Kingdom

F

Fengyuan Hu

S

Slavé Petrovski

S

Suneet Agarwal

B

Benjamin Raby

8Brigham and Women's Hospital, Channing Division of Network Medicine, Boston, United States

I

Immaculata De Vivo

3Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, United States

J

Jianwei Che

Department of Cancer Biology, Dana-Farber Cancer Institute

M

Margarete Fabre

G

George Vassiliou

J

Jonathan Mitchell

R

R. Coleman Lindsley

Dana-Farber Cancer Institute, Boston, Massachusetts, United States